Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type

Ann Oncol. 2007 Aug;18(8):1382-7. doi: 10.1093/annonc/mdm183.

Abstract

Background: Localized extranodal natural killer (NK)/T-cell lymphoma, nasal type, commonly has a low or low-intermediate risk of the international prognostic index (IPI), so the IPI has shown inconsistency in predicting prognosis. Thus, we analyzed Ki-67 expression and proposed a new prognostic model including Ki-67 expression for stage I/II extranodal NK/T-cell lymphoma.

Patients and methods: We studied Ki-67 expression and its relationship with prognosis in 50 patients with extranodal NK/T-cell lymphoma.

Results: The patients were dichotomized by the median value: low (<65%) versus high Ki-67 (> or =65%). High Ki-67 was associated with a worse overall survival (OS; P = 0.021) and disease-free survival (DFS; P = 0.044). In multivariate analysis, Ki-67 expression and primary site of involvement were found to be an independent prognostic factor for OS and DFS (P < 0.05). Based on these results, we proposed a new clinico-pathological prognostic model with Ki-67 expression and the primary site of involvement. It showed a high degree of correlation with worse OS and DFS (P < 0.001).

Conclusions: Ki-67 expression is predictive of prognosis, and our prognostic model may become a useful tool for predicting prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Ki-67 Antigen / biosynthesis*
  • Lymphoma, Extranodal NK-T-Cell / metabolism*
  • Lymphoma, Extranodal NK-T-Cell / mortality*
  • Lymphoma, Extranodal NK-T-Cell / therapy
  • Male
  • Middle Aged
  • Nose Neoplasms / metabolism*
  • Nose Neoplasms / mortality*
  • Nose Neoplasms / therapy
  • Prognosis
  • Radiotherapy

Substances

  • Antineoplastic Agents
  • Ki-67 Antigen